A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Lin, Ningjing ^a   Song, Yuqin ^a   Zheng, Wen ^a   Tu, Meifeng ^a   Xie, Yan ^a   Wang, Xiaopei ^a   Ping, Lingyan ^a   Ying, Zhitao ^a   Zhang, Chen ^a   Deng, Lijuan ^a   Liu, Weiping ^a   Zhu, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ECG ABNORMALITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG INJURY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CHEMORADIOTHERAPY; CLINICAL TRIAL; LYMPHOMA, T-CELL; MIDDLE AGED; NATURAL KILLER CELL; NOSE NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHEMORADIOTHERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84879466393     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-44     Document Type: Article

References (40)

1. Progress in understanding and managing natural killer-cell malignancies. Oshimi K, Br J Haematol 2007 139 4 532 544 10.1111/j.1365-2141.2007.06835.x 17916099 (Pubitemid 350043813)
2. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Suzuki R, Takeuchi K, Ohshima K, Nakamura S, Hematol Oncol 2008 26 2 66 72 10.1002/hon.847 18283711 (Pubitemid 351951334)
3. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, et al. Am J Clin Pathol 2012 138 3 429 434 10.1309/AJCP7YLTQPUSDQ5C 22912361
4. Novel therapeutic agents for cutaneous T-Cell lymphoma. Jain S, Zain J, O'Connor O, J Hematol Oncol 2012 5 1 24 10.1186/1756-8722-5-24 22594538
5. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J, et al. Eur J Haematol 2008 80 1 55 60 18028433 (Pubitemid 350265229)
6. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK, et al. J Clin Oncol 2000 18 1 54 63 10623693 (Pubitemid 30036336)
7. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, et al. J Clin Oncol 2006 24 1 181 189 10.1200/JCO.2005.03.2573 16382127 (Pubitemid 46630511)
8. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, Yoon JH, Kim GE, Int J Radiat Oncol Biol Phys 2004 59 4 1127 1137 10.1016/j.ijrobp.2003.12.006 15234048 (Pubitemid 38834307)
9. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, Okada J, Itami J, Ito H, Cancer 2006 106 3 609 615 10.1002/cncr.21656 16369986 (Pubitemid 43157624)
10. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J, Ann Hematol 2009 88 7 647 652 10.1007/s00277-008-0669-3 19107482
11. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thieblemont C, et al. Ann Oncol 2009 20 1 110 116 19454426
12. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Nagafuji K, Fujisaki T, Arima F, Ohshima K, Int J Hematol 2001 74 4 447 450 10.1007/BF02982090 11794702 (Pubitemid 33760107)
13. L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma. Obama K, Tara M, Niina K, Int J Hematol 2003 78 3 248 250 10.1007/BF02983802 14604284 (Pubitemid 37288512)
14. The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma. Yong W, Zhang Y, Zheng W, Zhonghua Xue Ye Xue Za Zhi 2000 21 11 577 579 11225247
15. Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma. Yong W, Zheng W, Zhang Y, Zhonghua Yi Xue Za Zhi 2001 81 13 773 775 11798962
16. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J, Int J Hematol 2003 78 2 163 167 10.1007/BF02983387 12953813 (Pubitemid 37021959)
17. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J, Hematol Oncol 2006 24 1 28 32 10.1002/hon.765 16323259
18. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, et al. Blood 2011 117 6 1834 1839 10.1182/blood-2010-09-307454 21123825
19. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, et al. J Clin Oncol 2011 29 33 4410 4416 10.1200/JCO.2011.35.6287 21990393
20. Extranodal natural killer/T-cell lymphoma: advances in the management. Jaccard A, Hermine O, Curr Opin Oncol 2011 23 5 429 435 10.1097/CCO. 0b013e328349aba6 21743325
21. Current and future management of NK/T-cell lymphoma based on clinical trials. Yamaguchi M, Int J Hematol 2012 96 5 562 571 10.1007/s12185-012-1189-4 23073619
22. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, Junker R, Blood 2003 101 7 2529 2533 10.1182/blood-2002-06-1901 12517808 (Pubitemid 36857608)
23. Extranodal NK/T- cell lymphoma, nasal type. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC PRESS, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, 4 2008 285 288
24. Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. Kim TM, Heo DS, Cancer Sci 2009 100 12 2242 2248 10.1111/j.1349-7006.2009.01319.x 19758393
25. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, et al. Eur J Cancer 2005 41 10 1402 1408 10.1016/j.ejca.2005.03.010 15963893 (Pubitemid 40826463)
26. Revised response criteria for malignant lymphoma. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. J Clin Oncol 2007 25 5 579 586 10.1200/JCO.2006.09.2403 17242396 (Pubitemid 350002966)
27. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: a prognostic model from a retrospective multicenter study. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS, J Clin Oncol 2006 24 4 612 618 10.1200/JCO.2005.04.1384 16380410 (Pubitemid 46630424)
28. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for improving survival of lymphoma study. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, et al. J Clin Oncol 2009 27 35 6027 6032 10.1200/JCO.2009.23.8592 19884539
29. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, et al. J Clin Oncol 2009 27 33 5594 5600 10.1200/JCO.2009.23.8295 19805668
30. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Kim GE, Lee SW, Chang SK, Park HC, Pyo HR, Kim JH, Moon SR, Lee HS, Choi EC, Kim KM, Radiother Oncol 2001 61 3 261 269 10.1016/S0167-8140(01)00428-5 11730995 (Pubitemid 33127230)
31. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R, Blood 2009 113 17 3931 3937 10.1182/blood-2008- 10-185256 19029440
32. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM, Hong RL, Cancer 2004 100 2 366 375 10.1002/cncr.11908 14716773 (Pubitemid 38063647)
33. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS, Blood 2012 120 15 2973 2980 10.1182/blood-2012-05- 431460 22919026
34. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, et al. Blood 2010 115 7 1351 1353 10.1182/blood-2009-09- 245951 20007809
35. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, et al. Blood 2002 99 6 1986 1994 10.1182/blood.V99.6.1986 11877270 (Pubitemid 34525479)
36. Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia. The Cooperation Group of Phase II Clinical Trial of PEG-Asp, Zhonghua Xue Ye Xue Za Zhi 2008 29 1 29 33 18512312
37. Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. Chauchet A, Michallet A-S, Berger F, Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront B, Petrella T, et al. J Hematol Oncol 2012 5 1 27 10.1186/1756-8722-5-27 22682004
38. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, et al. J Hematol Oncol 2011 4 1 34 10.1186/1756-8722-4-34 21843362
39. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, et al. Blood 2004 104 3 626 633 10.1182/blood-2003-06-2094 14982884 (Pubitemid 38970553)
40. Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. Jin X, Ding H, Ding N, Fu Z, Song Y, Zhu J, J Hematol Oncol 2012 5 1 51 10.1186/1756-8722-5-51 22897949